UNLABELLED: Right ventricular (RV) function is the major determinant of survival in patients with pulmonary hypertension. Yet, the pathophysiologic basis of RV disease is unresolved. We aimed to study the role of apoptosis in RV disease by monitoring it serially during disease progression using in vivo (99m)Tc-annexin-V ((99m)Tc-annexin) scintigraphy and study whether the reduction in apoptosis resulting from chronic treatment with valsartan can be detected by (99m)Tc-annexin scintigraphy. METHODS: RV disease after pulmonary hypertension was induced by monocrotaline injection in rats. The following 3 groups were studied: rats treated with monocrotaline (monocrotaline rats), rats treated with monocrotaline plus valsartan (valsartan rats), and age-matched controls (control rats). Serial echocardiography and in vivo (99m)Tc-annexin scintigraphy were performed. Apoptosis was confirmed by (99m)Tc-annexin autoradiography and terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling. Fibrosis was assessed by picrosirius red staining. RESULTS: In monocrotaline rats, in vivo (99m)Tc-annexin uptake peaked early and declined thereafter but remained elevated, compared with baseline. These stage-dependent changes of in vivo (99m)Tc-annexin uptake were paralleled by changes in autoradiography and terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling. Valsartan rats had longer RV failure-free survival than did monocrotaline rats and had reduced apoptosis. These changes were accompanied by commensurate delays in RV hypertrophy and RV dilation. Valsartan rats also had less fibrosis than monocrotaline rats at all disease stages. CONCLUSION: RV disease progression is associated with an early increase in RV apoptosis, as monitored using serial in vivo (99m)Tc-annexin scintigraphy. Delay in RV disease progression by valsartan is accompanied by reduction in RV apoptosis. Apoptosis plays a role in RV disease progression and may be assessed by serial in vivo (99m)Tc-annexin scintigraphy.
UNLABELLED: Right ventricular (RV) function is the major determinant of survival in patients with pulmonary hypertension. Yet, the pathophysiologic basis of RV disease is unresolved. We aimed to study the role of apoptosis in RV disease by monitoring it serially during disease progression using in vivo (99m)Tc-annexin-V ((99m)Tc-annexin) scintigraphy and study whether the reduction in apoptosis resulting from chronic treatment with valsartan can be detected by (99m)Tc-annexin scintigraphy. METHODS: RV disease after pulmonary hypertension was induced by monocrotaline injection in rats. The following 3 groups were studied: rats treated with monocrotaline (monocrotalinerats), rats treated with monocrotaline plus valsartan (valsartanrats), and age-matched controls (control rats). Serial echocardiography and in vivo (99m)Tc-annexin scintigraphy were performed. Apoptosis was confirmed by (99m)Tc-annexin autoradiography and terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling. Fibrosis was assessed by picrosirius red staining. RESULTS: In monocrotalinerats, in vivo (99m)Tc-annexin uptake peaked early and declined thereafter but remained elevated, compared with baseline. These stage-dependent changes of in vivo (99m)Tc-annexin uptake were paralleled by changes in autoradiography and terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling. Valsartanrats had longer RV failure-free survival than did monocrotalinerats and had reduced apoptosis. These changes were accompanied by commensurate delays in RV hypertrophy and RV dilation. Valsartanrats also had less fibrosis than monocrotalinerats at all disease stages. CONCLUSION: RV disease progression is associated with an early increase in RV apoptosis, as monitored using serial in vivo (99m)Tc-annexin scintigraphy. Delay in RV disease progression by valsartan is accompanied by reduction in RV apoptosis. Apoptosis plays a role in RV disease progression and may be assessed by serial in vivo (99m)Tc-annexin scintigraphy.
Authors: Ingeborg Friehs; Ben Illigens; Ivan Melnychenko; Tachi Zhong-Hu; Elisabeth Zeisberg; Pedro J Del Nido Journal: J Surg Res Date: 2012-08-17 Impact factor: 2.192
Authors: Soban Umar; Jong-Hwan Lee; Enno de Lange; Andrea Iorga; Rod Partow-Navid; Aneesh Bapat; Arnoud van der Laarse; Rajeev Saggar; Rajan Saggar; Dirk L Ypey; Hrayr S Karagueuzian; Mansoureh Eghbali Journal: Circ Arrhythm Electrophysiol Date: 2011-12-22
Authors: Marina Dias-Neto; Ana Luísa-Neves; Sónia Pinho; Nádia Gonçalves; Maria Mendes; Catarina Eloy; José M Lopes; Daniel Gonçalves; Manuel Ferreira-Pinto; Adelino F Leite-Moreira; Tiago Henriques-Coelho Journal: Pediatr Cardiol Date: 2015-01-22 Impact factor: 1.655
Authors: Maria E Campian; Hanno L Tan; Astrid F van Moerkerken; Raymond Tukkie; Berthe L F van Eck-Smit; Hein J Verberne Journal: Eur J Nucl Med Mol Imaging Date: 2011-05-07 Impact factor: 9.236
Authors: Michael L Paffett; Jacob Hesterman; Gabriel Candelaria; Selita Lucas; Tamara Anderson; Daniel Irwin; Jack Hoppin; Jeffrey Norenberg; Matthew J Campen Journal: PLoS One Date: 2012-07-17 Impact factor: 3.240
Authors: Neil MacRitchie; Giora Volpert; Mohammed Al Washih; David G Watson; Anthony H Futerman; Simon Kennedy; Susan Pyne; Nigel J Pyne Journal: Cell Signal Date: 2016-04-06 Impact factor: 4.315